Madhu Kumar
Stock Analyst at Goldman Sachs
(3.58)
# 876
Out of 4,711 analysts
153
Total ratings
55.34%
Success rate
18.69%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $122.97 | +37.43% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $4.35 | +37.93% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $26.86 | -3.20% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $15.84 | +7.32% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.86 | +115.05% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $164.83 | -5.96% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $48.87 | +8.45% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $6.25 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $19.45 | +275.32% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $33.21 | +324.57% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $13.08 | +159.94% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $7.38 | -18.70% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $15.48 | -9.56% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $12.72 | +65.09% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $30.78 | -83.76% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.31 | +510.69% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $18.48 | +381.60% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.66 | +809.09% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.88 | +1,036.23% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $12.18 | +597.87% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.64 | +2,278.05% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $16.98 | +235.69% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.21 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.05 | +29,408.20% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $7.34 | +172.48% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.97 | +10,209.28% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $44.78 | -21.84% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $2.91 | +1,961.86% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $7.10 | +463.38% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $15.21 | +3,213.61% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $245.44 | -6.29% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $1.59 | +3,673.58% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $2.24 | +1,685.71% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $32.20 | -33.23% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $40.72 | -42.29% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $122.97
Upside: +37.43%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $4.35
Upside: +37.93%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $26.86
Upside: -3.20%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $15.84
Upside: +7.32%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.86
Upside: +115.05%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $164.83
Upside: -5.96%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $48.87
Upside: +8.45%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $6.25
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $19.45
Upside: +275.32%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $33.21
Upside: +324.57%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $13.08
Upside: +159.94%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $7.38
Upside: -18.70%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $15.48
Upside: -9.56%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $12.72
Upside: +65.09%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $30.78
Upside: -83.76%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.31
Upside: +510.69%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $18.48
Upside: +381.60%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.66
Upside: +809.09%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.88
Upside: +1,036.23%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $12.18
Upside: +597.87%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.64
Upside: +2,278.05%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $16.98
Upside: +235.69%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $3.05
Upside: +29,408.20%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $7.34
Upside: +172.48%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.97
Upside: +10,209.28%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $44.78
Upside: -21.84%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $2.91
Upside: +1,961.86%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $7.10
Upside: +463.38%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $15.21
Upside: +3,213.61%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $245.44
Upside: -6.29%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $1.59
Upside: +3,673.58%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $2.24
Upside: +1,685.71%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $32.20
Upside: -33.23%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $40.72
Upside: -42.29%